Some Investors May Be Willing To Look Past Harmony Biosciences Holdings' (NASDAQ:HRMY) Soft Earnings
Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) stock was strong despite it releasing a soft earnings report last week. However, we think the company is showing some signs that things are more pro
Results: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Harmony Biosciences Holdings First Quarter 2024 Earnings: EPS Beats Expectations
Harmony Biosciences Outperforms Expectations With Strong Q1 Results and Strategic Acquisition
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 13.6x Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) may be sending bullish signals at the moment, given that almost half of all companies in the United
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)
Harmony Biosciences Holdings Sell Rating: Concerns Over Product Differentiation, Patent Litigation, and R&D Pipeline
Harmony Biosciences Is Maintained at Buy by Needham
Harmony Biosciences Is Maintained at Buy by Needham
Needham Maintains Buy on Harmony Biosciences, Raises Price Target to $52
Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $50 to $52.
Harmony Biosciences Holdings Inc (HRMY) Q1 2024 Earnings Call Transcript Highlights: Strong ...
Earnings Call Summary | Harmony Biosciences(HRMY.US) Q1 2024 Earnings Conference
The following is a summary of the Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript:Financial Performance:Harmony Biosciences reported Q1 net revenues of $154.6 million, a 30%
Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript
Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript
Harmony Biosciences' (HRMY) Stock Momentum Builds On Strong Financials
The shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) are undergoing a noticeable ascent during the current-market session today. As of the last check, HRMY shares were exhibiting a noteworthy surge of 12.82%, reaching a valuation of $33.00. This considerable uptick of HRMY shares on the US stock charts appears to be substantiated by the ...
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
Tuesday, Harmony Biosciences (NASDAQ:HRMY) announced the acquisition of Epygenix Therapeutics, adding a rare epilepsy franchise to its expanding late-stage pipeline of central nervous system (CNS) ass
Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise
Harmony Biosciences Holdings (HRMY) said Tuesday it acquired Epygenix Therapeutics, a precision medicine-based biopharmaceutical company. Harmony paid $35 million in cash, with the potential for up to
Harmony Biosciences Stock Gains 10% On Q1 Results
Annovis Bio, Cyclacel Pharmaceuticals, Biodexa Pharmaceuticals Among Healthcare Movers
Analysts' Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Decibel Cannabis Company (OtherDBCCF) and Avid Bioservices (CDMO)
Needham: Reiterates Harmony Biosciences (HRMY.US) rating, adjusted from buy to buy rating, target price of $50.00.
Needham: Reiterates Harmony Biosciences (HRMY.US) rating, adjusted from buy to buy rating, target price of $50.00.
No Data